| Literature DB >> 6505269 |
G Lundell, H Blomgren, B Cedermark, C Silfverswärd, T Theve, U Ohman.
Abstract
Eighteen patients with advanced and inoperable colorectal adenocarcinomas were treated with high doses of alpha 2 Interferon (Schering-Plough Corporation). The patients were randomized to receive either subcutaneous injections of 20 X 10(6) I.U./m2 three times weekly for 3 months, or pulsed treatments of 50 X 10(6) I.U./m2 daily, given intravenously, for 5 consecutive days every 4 weeks. No objective tumour regression was seen in any patient. The side effects were considerable.Entities:
Mesh：
Substances：
Year: 1984 PMID： 6505269 DOI： 10.1016/s0167-8140(84)80020-1
Source DB: PubMed Journal: Radiother Oncol ISSN： 0167-8140 Impact factor: 6.280